Back to Agenda
Ethics in the Era of Precision Medicine and Advancing Technologies
Session Chair(s)
James Wabby, MHS
Global Head, Regulatory Affairs, Emerging Technologies and Combination Products
AbbVie, United States
Precision medicine integrates advanced technology and healthcare to tailor treatments to individuals, aiming to enhance outcomes. However, the rise of artificial intelligence (AI) and advanced technologies in this field introduces new ethical complexities. Privacy, informed consent, and social justice remain central concerns, but evolving technologies brings additional challenges, such as biases in algorithmic predictions and the transparency of decision-making processes. AI-driven models used to predict treatment outcomes or develop personalized care plans can reflect societal biases if trained on unrepresentative or flawed data. This raises concerns about fairness, as patients could be unjustly stratified based on genetic, racial, or socioeconomic factors. Precision medicine, which stratifies patients by genetic profiles, risks perpetuating discrimination or exacerbating health disparities.
Learning Objective : Understanding of bioethical impact within the next generation of medcine; Ackowledge the importance of the inclusion of diverse, representative populations and handling of incidental findings—unanticipated results that arise during genetic screening—must be ethically integrated into research protocol.
Speaker(s)
Ethics in the Era of Precision Medicine and Advancing Technologies
James Wabby, MHS
AbbVie, United States
Global Head, Regulatory Affairs, Emerging Technologies and Combination Products
Ethics in the Era of Precision Medicine and Advancing Technologies
Amanda Burkhardt, PhD
University of Southern California, United States
Assistant Professor, Alfred E. Mann School of Pharmacy and Pharma Sciences
Have an account?